This site is intended for healthcare professionals

EMA approves extended filing for Spikevax as booster for COVID-19.

Read time: 1 mins
Last updated:8th Oct 2021
Published:7th Oct 2021
Moderna announced that the European Medicines Agency (EMA) has authorized a third dose of Spikevax, the Moderna COVID-19 vaccine, given at least 28 days after the second dose to severely immunocompromised individuals 12 years of age or older.

A growing number of studies have shown the benefit of a third dose of COVID-19 vaccine in immunocompromised subjects.

In particular, a recent double-blind, randomized controlled trial of 120 individuals who had undergone solid organ transplant procedures (heart, kidney, kidney-pancreas, liver, lung, pancreas) demonstrated that a third dose of the Moderna COVID-19 vaccine improved immune response compared to placebo. In the study, the third dose was generally well tolerated.

Condition: Coronavirus/COVID-19 Infection
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights